08. High-definition insights into drug resistant tuberculosis
Saturday, 05 December 2015, 12:30-13:30

Chair: Shu- Hua WANG (USA)
Track: Drug resistance determination - molecular and phenotypic

EP-161-05  Specific gyrA gene mutations predict poor treatment outcome in drug-resistant tuberculosis
L Rigouts, N Coeck, G Gumusboga, - Maug, Ma Hossen, H L Rieder, B De Jong, V D Armand (Belgium, Bangladesh, Switzerland)

EP-162-05  Contribution of efflux pumps to rifampicin resistance in clinical isolates of M. tuberculosis
A Narang, S Porwal, K Garima, A Bhandekar, K Shrivastava, R Prasad, M Bose, M Varma Basil (India)

EP-163-05  Use of whole genome sequencing to identify mutations related to phenotypic resistance to delamanid and bedaquiline in M. tuberculosis
A Cabibbe, S Battaglia, E Schena, E Borroni, P Miotto, D M Cirillo (Italy)

EP-164-05  Characterization of resistance to rifampicin and isoniazid among Beijing Mycobacterium tuberculosis isolates in Kazakhstan
U Kozhamkulov, A Akhmetova, V Bismilda, L Chingisova, A Akilzhanova (Kazakhstan)

EP-165-05  Sequencing-based detection of rpoB gene mutations in Mycobacterium tuberculosis strains from Malawi
T Chikaonda, I Kets, N Nguluwe, I Thengolose, F Nyakwawa, W Stevens, L Scott, M Hosseinipour (Malawi, South Africa)

EP-166-05  Genetic markers of drug resistance and their association with clinical outcomes in patients with MDR-TB or XDR-TB
J Limberis, E Pietersen, J Jaisubash Jayakumar G Theron, K Dheda, L Smith, R M Warren, T Clark (South Africa)

EP-167-05  Whole genome sequencing reveals accumulation of single nucleotide polymorphisms (SNPs) associated with treatment failure
L Malinga, J Brand, T Abeel, A Earl, M Van Der Walt (South Africa)

EP-168-05  Use of DNA from AFB smears to perform high-throughput sequencing based surveillance for drug-resistant Mycobacterium tuberculosis in Afghanistan
J Mancuso, M Rowneki, N Hamraz, P Du, G Davis, R Blakemore, D Alland, N Aronson (USA, Afghanistan)

EP-169-05  Association between specific mutations conferring resistance to rifampicin and isoniazid and baseline resistance to other anti-tuberculosis drugs
E Click, E Kurbatova, H Alexander, T Dalton, J Ershova, P Cegielski, J Posey (USA)